OakChart

Purple Biotech Ltd ADR

PPBTHealthcare·Biotechnology·Israel·Nano·NASD·Nov 11 • 3:58 PM ET

1.49+0.15 (11.19%)
2026-11-12 00:10 CET
Market cap
2.17 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-24.64 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-28.06
P/E
-
Compare

Price

PPBT against its 20, 50 and 200-day averages
2050200earnings
2.004.006.008.0038.4M76.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PPBTclose 1.4920-day 1.1750-day 1.41200-day 2.821.4952w low

83.3% under the 52-week high of 8.90 on 1 Dec 2025. 52-week low 0.91 on 28 Oct 2026. Last 15 sessions, 63.7% high to low

Volume 0.02× normal · the line is the 50-bar volume average

Profile

PPBT
52-week range, 7% of the way up
0.918.90

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

Employees10
IPONov 20, 2015
Beta0.73
ATR, 14d0.13
Rel volume0.02
Short float0.97%
Insider own0.10%
Inst own6.62%

Snapshot

6 groups

Valuation

Index-
Market Cap2.41M
Enterprise Value-3.62M
Income-24.64M
Sales0.00M
Book/sh7.58
Cash/sh3.77
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees10
IPONov 20, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.20
P/C0.40
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.70
Current Ratio3.70
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-28.06
EPS next Y-1.01
EPS next Q-2.88
EPS this Y89.57%
EPS next Y82.37%
EPS next 5Y78.99%
EPS past 3/5Y38.10% 29.92%
Sales past 3/5Y- -
EPS Y/Y TTM-151.47%
Sales Y/Y TTM-
EPS Q/Q110.06%
Sales Q/Q-
EarningsAug 07 BMO
EPS/Sales Surpr.58.16% -

Ownership

Insider Own0.10%
Insider Trans0.00%
Inst Own6.62%
Inst Trans42.65%
ROA-101.51%
ROE-111.29%
ROIC-200.79%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2027.83%
SMA506.02%
SMA200-47.07%
Trades-

Technical

Shs Outstand1.62M
Shs Float1.62M
Short Float0.97%
Short Ratio0.01
Short Interest0.02M
52W High8.90 -83.26%
52W Low0.91 63.74%
Volatility13.58% 9.82%
ATR (14)0.13
RSI (14)64.25
Beta0.73
Rel Volume0.02
Avg Volume1.24M
Volume20,262

Performance

Perf Week22.63%
Perf Month9.56%
Perf Quarter-0.33%
Perf Half Y-62.26%
Perf YTD-77.34%
Perf Year-82.05%
Perf 3Y-99.32%
Perf 5Y-99.83%
Perf 10Y-99.98%
Recom1.00
Target Price17.00
Prev Close1.34
Price1.49
Change %11.19%

Peers

Mkt cap
TickerCompanyMkt cap
BLRXBioline Rx Ltd ADR7.42M
CANFCan-Fite Biopharma Ltd ADR4.71M
SLXNSilexion Therapeutics Corp2.04M
NXTCNextcure Inc27.37M
CMPXCompass Therapeutics Inc149.51M
ENLVEnlivex Ltd1.93M
IMMPImmutep Limited ADR26.24M
ALXOAlx Oncology Holdings Inc154.87M
ELTXElicio Therapeutics Inc46.14M
SCNIScinai Immunotherapeutics Ltd ADR0.69M

News

latest 14 of 200
  • Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium (GlobeNewswire) +13.86%
  • Purple Biotech U.S. Patent Allowance Strengthens CAPTN-3 Multispecific Antibody Protection (InvestorsHub) +19.28%
  • New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies (GlobeNewswire)
  • Purple Biotech Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Purple Biotech Presents New IM1240 Preclinical Data Showing Anti-Tumor Activity and Broad Therapeutic Window (PPBT) (InvestorsHub) -47.97%
  • Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window (GlobeNewswire)
  • Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire) +6.78%
  • Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240 (GlobeNewswire)
  • Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform (GlobeNewswire) -8.08%
  • Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform (GlobeNewswire)
  • Purple Biotech Regains Compliance with Nasdaq (GlobeNewswire)
  • Purple Biotech Announces CEO Transition (GlobeNewswire) +6.77%
  • Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
  • Purple Biotech Announces Plan to Implement ADS Ratio Change (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-07-0.410-0.980-0.4100.000.001
2026Q12026-05-15-0.090-0.380-0.1000.000.001
2025Q42026-03-13-19.850-3.400-25.4980.000.001
2025Q32025-11-14-2.900--2.8730.00--
2025Q22025-08-06-4.000-2.100-4.0450.000.001
2025Q12025-05-21-1.700--1.6910.00--
2024Q42025-03-10-2.600-2.200-1.5930.000.001
2024Q32024-11-15-3.900-12.000-3.8310.000.001
2024Q22024-08-16-18.000-23.000-17.3120.000.002
2024Q12024-05-21-28.000-38.000-29.3220.000.002
2023Q42024-03-05-38.000-38.000-39.6430.000.003
2023Q32023-11-21-46.000-45.340-46.8730.000.003
2023Q22023-08-22-50.000-51.340-48.3230.000.003
2023Q12023-05-16-50.000-72.000-46.5010.000.002
2022Q42023-02-08-66.000-50.000-64.8860.000.002
2022Q32022-11-08-54.000-42.000-53.0510.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY-140-100-2,6150.000.00
2018FY-780--729.621.00-
2020FY488-8.000-327.641.004.70
2022FY-240-227-233.560.000.00
2023FY-180-183.33-161.080.000.00
2024FY-49.900-8.300-28.1330.000.00
2025FY-54.960-12.200-49.9000.000.00
2026FY--5.730--0.00
2027FY--1.010--0.00
2028FY--0.510--0.00
2029FY--0.370--0.00
2030FY--0.120--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-071000.000.000.00
2026Q3S2026-05-151000.000.000.00
2026Q3S2026-03-131000.000.000.00
2026Q3S2025-11-171000.000.000.00
2026Q3E2026-10-21100-2.88-2.88-2.88
2026Q3E2026-08-07101-2.88-2.88-2.88
2026Q3E2026-08-06101-2.88-2.88-2.88
2026Q3E2026-07-29100-1.73-1.73-1.73
2026Q3E2026-05-15101-1.73-1.73-1.73
2026Q3E2026-03-13110-0.42-0.42-0.42
2026Q3E2025-11-17100-5.10-5.10-5.10
2026Q2S2026-05-151000.000.000.00
2026Q2S2026-03-131000.000.000.00
2026Q2S2025-11-171000.000.000.00

Estimate history

EPS, annual-2615.35-729.622-606.055-327.643-206.703-233.563-161.084-28.133-55.396-28.0646
Period201720182019202020212022202320242025TTM
EPS, quarterly-17.312-3.831-1.593-1.691-4.045-2.873-25.498-0.10.407
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.1010.9971.0030000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0060.0080.010.0860.0890.0920.1230.2590.9291.618
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.1380.1740.2590.2650.2840.9030.9290.9291.618
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.001.001.00
Cost of Goods Sold Incl. D&A0.250.200.190.200.200.230.24--
Gross Profit-0.25-0.20-0.19-0.20-0.20-0.23-0.24--
Selling, General and Administrative Excl. Other7.676.8310.6722.0222.3117.7213.108.2410.42
Research and Development4.373.767.6616.9916.2611.847.292.685.25
Other Operating Expense0.000.000.200.000.000.000.00-0.00
Operating Income-7.92-7.03-11.06-22.21-22.51-17.95-13.33-7.42-9.43
Interest Expense1.020.990.452.180.070.080.060.080.01
Unusual Expense18.3318.92-3.97-4.00-0.240.0015.76-1.75-3.47
Net Income Before Taxes-24.74-26.70-7.31-19.93-21.67-17.84-28.90-5.70-5.55
Income Taxes0.000.000.000.000.000.000.000.220.00
Consolidated Net Income-24.74-26.70-7.31-19.93-21.67-17.84-28.90-5.91-5.55
Net Income From Continuing Operations-24.64-26.60-7.27-19.83-21.58-17.75-28.83-5.87-5.18
Net Income-24.64-26.60-7.27-19.83-21.58-18.40-28.20-5.87-5.18
EPS (Recurring)-10.87-27.80-38.88-183.85-235.41-206.70-199.41-732.90-1,071.89
EPS (Basic, Before Extraordinaries)-28.06-55.40-28.13-161.08-233.56-206.70-327.64-606.05-729.62
EPS (Diluted)-28.06-55.40-28.13-161.08-233.56-206.70-327.64-606.05-729.62
EBITDA-7.67-6.83-10.87-22.02-22.31-17.72-13.10-7.24-9.43
Non-Operating Income (Expense)2.530.240.230.460.660.190.250.050.42
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.581.602.011.951.111.602.050.980.59
Price To Sales Ratio------65.1215.059.41
Operating Margin--------739.60-946.30
Net Margin--------585.00-520.00
Shares Outstanding1.620.930.260.120.090.090.090.010.01
Market Capitalization2.172.1712.1316.7024.9069.2465.5715.2510.57

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.070.060.050.060.050.040.040.05
Gross Profit-0.07-0.06-0.05-0.06-0.05-0.04-0.04-0.05
Selling, General and Administrative Excl. Other1.252.182.931.321.211.350.982.09
Research and Development0.711.231.840.590.560.760.461.35
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.32-2.24-2.98-1.37-1.26-1.40-1.02-2.14
Interest Expense0.010.030.970.01-0.03-0.51
Unusual Expense-1.700.0020.030.000.000.00-0.08-1.85
Net Income Before Taxes0.45-0.09-23.79-1.31-1.11-0.45-0.42-0.67
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income0.45-0.09-23.79-1.31-1.11-0.45-0.42-0.67
Net Income From Continuing Operations0.45-0.09-23.69-1.31-1.11-0.45-0.41-0.66
Net Income0.45-0.09-23.69-1.31-1.11-0.45-0.41-0.66
EPS (Recurring)-0.68-0.09-10.40-2.87-4.05-1.70-1.81-11.27
EPS (Basic, Before Extraordinaries)0.41-0.10-25.50-2.87-4.05-1.69-1.59-3.83
EPS (Diluted)0.41-0.10-25.50-2.87-4.05-1.69-1.59-3.83
EBITDA-1.25-2.18-2.93-1.32-1.21-1.35-0.98-2.09
Non-Operating Income (Expense)0.082.190.200.070.150.980.530.13
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.050.091.240.200.06--1.210.13
Shares Outstanding1.620.930.930.900.280.270.260.17
Market Capitalization2.173.756.115.196.667.0512.139.66

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments9.578.5215.4132.1147.2057.816.406.687.44
Short Term Receivables0.000.000.000.000.000.501.490.740.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.290.380.381.141.270.980.411.090.55
Total Current Assets9.878.9115.7933.2648.4759.288.308.517.98
Net Property, Plant & Equipment0.350.290.470.680.900.970.240.040.03
Total Investments and Advances0.000.000.000.000.353.070.000.000.00
Intangible Assets7.3627.8428.0420.6820.4820.486.176.176.17
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets17.5737.0444.3054.6270.2083.8014.7214.7214.18
Short Term Debt Incl. Current Port. of LT Debt0.240.180.190.190.200.210.200.000.00
Accounts Payable2.071.453.532.131.471.201.250.700.22
Other Current Liabilities5.442.353.464.732.581.692.112.613.76
Total Current Liabilities7.753.997.187.064.253.103.553.313.97
Long Term Debt0.000.000.160.320.550.690.030.000.00
Provision for Risks Charges0.160.140.140.150.290.270.290.400.49
Other Liabilities0.000.002.520.000.000.000.000.001.03
Total Liabilities7.914.1310.017.525.094.053.863.725.50
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity9.7132.8634.2146.9164.8379.3910.4210.527.41
Total Shareholders Equity9.7132.8634.2146.9164.8379.3910.4210.527.41
Accumulated Minority Interest-0.050.050.090.190.280.360.440.481.28
Total Equity9.6632.9134.3047.1065.1179.7510.8611.008.69
Total Liabilities & Stockholders Equity17.5737.0444.3054.6270.2083.8014.7214.7214.18
Book Value Per Share10.45127.09277.89507.66728.40922.561,065.301,314.601,320.28
Tangible Book Value Per Share2.5319.4150.07283.82498.26684.55434.36543.56220.28
Full-Time Employees1092020191391010
Price to Book Ratio0.180.370.430.481.070.831.461.001.76
Return on Assets-97.40-17.89-40.09-34.58-23.06-58.52-39.87-35.86-84.39
Return on Equity-124.94-21.69-48.89-38.63-24.62-64.19-56.04-58.12-118.11
Return on Invested Capital-273.79-22.14-57.69-45.70-28.14-35.21-56.17-49.26-165.65
Quick Ratio1.272.232.204.7111.4119.142.342.572.01
Current Ratio1.272.232.204.7111.4119.142.342.572.01

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-24.79-26.70-7.31-19.93-21.67-17.84-28.90-5.91-5.55
Depreciation0.250.200.190.200.200.230.240.180.01
Other Funds (Non Cash)17.3220.15-2.680.281.822.2618.32-0.08-2.45
Funds from Operations-7.22-6.35-9.81-19.45-19.66-15.35-10.35-5.82-7.99
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.440.81-4.350.273.240.74-3.460.34-0.54
Cash from Operating Activities-7.66-5.54-14.16-19.18-16.41-14.60-13.81-5.48-8.53
Capital Expenditures0.00-0.000.00-0.00-0.23-0.12-0.16-0.01-0.02
Net Assets From Acquisitions0.000.000.00-3.540.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.070.000.00
Purchase or Sale of Investments0.150.450.1916.6419.7413.17-49.971.521.96
Purchase of Investments-0.01-0.010.000.000.00--49.970.000.00
Sale Or Maturity of Investments0.160.460.1916.6419.7413.170.001.521.96
Other Uses0.000.000.000.000.00-0.370.00-2.110.00
Other Sources0.000.000.000.000.000.001.720.000.00
Cash from Investing Activities0.150.450.1913.0919.5112.68-48.34-0.601.94
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock8.246.637.035.661.341.7469.175.457.93
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock8.246.637.035.661.341.7469.175.457.93
Proceedsfrom Stock Options3.972.867.321.331.340.5426.03-0.26-0.41
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00-0.170.00
Change in Long Term Debt0.000.000.000.000.000.000.00-0.170.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00-0.170.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities7.996.416.855.491.181.5968.995.287.93
Exchange Rate Effect0.030.01-0.000.05-0.15-0.020.060.02-0.14
Net Change in Cash0.511.33-7.12-0.544.12-0.366.91-0.781.21
Free Cash Flow--5.54-14.16-19.18-16.44-14.72-13.96-5.49-8.54
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments6.106.439.5710.455.927.09
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.480.350.290.320.390.43
Total Current Assets6.596.789.8710.776.317.52
Net Property, Plant & Equipment0.220.280.350.450.220.24
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets7.367.367.3627.8427.8427.84
Other Assets0.000.000.000.000.000.00
Total Assets14.1714.4217.5739.0634.3835.59
Short Term Debt Incl. Current Port. of LT Debt0.130.180.240.210.100.14
Accounts Payable0.490.842.070.610.670.87
Other Current Liabilities1.163.575.445.251.421.75
Total Current Liabilities1.784.597.756.062.192.76
Long Term Debt0.000.000.000.050.000.00
Provision for Risks Charges0.170.160.160.140.140.14
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.954.757.916.252.332.90
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity12.279.729.7132.7732.0132.65
Total Shareholders Equity12.279.729.7132.7732.0132.65
Accumulated Minority Interest-0.06-0.06-0.050.040.040.05
Total Equity12.219.669.6632.8232.0532.70
Total Liabilities & Stockholders Equity14.1714.4217.5739.0634.3835.59
Book Value Per Share7.5810.4610.4536.29112.74123.17
Tangible Book Value Per Share3.032.542.535.4614.6618.13
Full-Time Employees--10---
Price to Book Ratio0.180.390.630.160.210.22
Return on Assets-101.51-104.76-97.27-8.85-7.49-10.40
Return on Equity-111.29-123.65-124.77-10.55-8.60-12.33
Return on Invested Capital3.66-0.88-243.90-3.99-3.46-1.38
Quick Ratio3.701.481.271.782.882.72
Current Ratio3.701.481.271.782.882.72

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income0.44-0.09-23.83-1.31-1.10-0.46
Depreciation0.070.060.050.060.050.05
Other Funds (Non Cash)-1.70-2.0220.840.20-0.06-0.83
Funds from Operations-1.18-2.05-2.94-1.06-1.11-1.24
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.36-1.031.900.05-0.42-0.71
Cash from Operating Activities-2.54-3.07-1.04-1.01-1.54-1.95
Capital Expenditures-0.000.000.000.00-0.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.00-0.010.010.000.00
Purchase or Sale of Investments-0.010.00-0.160.320.060.22
Purchase of Investments-0.010.000.01-0.01-0.010.00
Sale Or Maturity of Investments-0.000.00-0.160.320.070.22
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.00-0.160.330.060.22
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.200.000.385.660.420.17
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.200.000.385.660.420.17
Proceedsfrom Stock Options2.200.00-0.171.940.420.17
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities2.14-0.060.325.590.380.11
Exchange Rate Effect0.05-0.01-0.00-0.020.04-0.01
Net Change in Cash-0.36-3.14-0.884.89-1.06-1.63
Free Cash Flow-2.54-3.07---1.54-1.95

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.97%0.0M1.6M1.26M
2026-10-151.01%0.0M1.6M1.26M
2026-09-301.12%0.0M1.6M1.28M
2026-09-155.00%0.1M1.6M1.30M
2026-08-311.74%0.0M1.6M222.25K
2026-08-141.61%0.0M1.6M325.83K
2026-07-310.65%0.0M1.6M305.49K
2026-07-151.13%0.0M1.6M310.35K
2026-06-301.67%0.0M1.6M301.66K
2026-06-156.28%0.1M1.6M288.53K
2026-05-294.86%0.0M1.0M116.83K
2026-05-150.80%0.0M0.9M13.59K
2026-04-301.13%0.0M0.9M13.80K
2026-04-150.86%0.0M0.9M13.35K
2026-03-311.07%0.0M0.9M12.70K
2026-03-130.89%0.0M0.9M14.05K
2026-02-270.86%0.0M0.9M31.16K
2026-02-130.83%0.0M0.9M33.39K
2026-01-301.35%0.0M0.9M49.20K
2026-01-151.04%0.0M0.9M731.16K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.003.000.420.0004.000.000.0000.0000.000
call5.000.005.000.300.0001570.000.0000.0000.000
call7.500.005.000.050.00038.000.000.0000.0000.000
put2.500.005.001.030.0000.000.000.0000.0000.000
put5.001.606.000.000.0000.000.000.0000.0000.000
put7.504.108.500.000.0000.000.000.0000.0000.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13G/ASEC
2026-11-06F-3/ASEC
2026-10-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-05SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-09-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-02SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-10SEC
2026-08-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-07SEC
2026-07-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-29SEC
2026-06-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-23SEC
2026-06-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-11SEC
2026-05-20F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-05-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-15SEC
2026-05-13SCHEDULE 13G/ASEC
2026-04-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-27SEC
2026-04-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-23SEC
2026-04-173Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-073Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-063Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-313Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-303/A2026-03-18SEC
2026-03-303Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-273Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-25SEC
2026-03-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-18SEC
2026-03-1920-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-17SEC
2026-03-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-13SEC
2026-02-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-25SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
SmartHarvest Portfolios, LLC3.16%
HRT FINANCIAL LP0.90%
CITADEL ADVISORS LLC0.81%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.79%
Independent Advisor Alliance0.73%
UBS Group AG0.40%
Arax Advisory Partners0.09%
RHUMBLINE ADVISERS0.05%
MORGAN STANLEY0.01%
ROYAL BANK OF CANADA0.01%

Funds

Fund% owned
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. PPBT. Cached 15 minutes.

Some panels did not load: ratings, insider.